JAC Advance Access originally published online on August 13, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 435-440
© 2003 The British Society for Antimicrobial Chemotherapy
Gatifloxacin and the elderly: pharmacokinetic–pharmacodynamic rationale for a potential age-related dose reduction
1 Division of Infectious Diseases, Cognigen Corporation, Buffalo, 395 Youngs Road, Buffalo, NY 14221–5831; 2 University of the Pacific, School of Health Sciences, Stockton, CA; 3 School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
Received 3 December 2002; returned 26 February 2003; revised 30 May 2003; accepted 16 June 2003
Objectives: Recently, anecdotal reports via the FDA’s MedWatch reporting system have documented rare but serious hyperglycaemia in elderly patients receiving gatifloxacin. One possible factor contributing to these events may be gatifloxacin overexposure, resulting from age-related decreases in renal function in elderly patients predisposed to glycaemic alterations. These analyses examine gatifloxacin exposure in 10 patients with severe hyperglycaemia, provide a pharmacokinetic–pharmacodynamic (PK-PD) rationale for a potential age-related dose reduction to avoid high exposures, and evaluate the likely impact of such a dose reduction on clinical efficacy in this specific patient population.
Methods: First, a previously derived population pharmacokinetic model, with patient demographics, was used to estimate gatifloxacin AUC0–24 following a dosage regimen of 400 mg/24 h in 10 index patients with severe hyperglycaemia. Second, the population pharmacokinetic model and patient demographic data from 2696 patients aged 
65 years from two New Drug Application (NDA) databases were used to estimate AUC0–24 following dosage regimens for gatifloxacin of 200 and 400 mg/24 h. Finally, Monte Carlo simulation was utilized to assess the probability of achieving PK-PD target exposures against Streptococcus pneumoniae in elderly patients using these regimens.
Results: The mean estimated AUC0–24 among severe hyperglycaemia cases was 74 mg•h/L (range 57–100). Gatifloxacin AUC0–24 exposures for the 400 mg regimen were predicted to be higher in patients aged 65 years and similar to the severe hyperglycaemia cases. The probability of AUC0–24 60 and 70 in patients aged 65 years for the 200 mg regimen was 0.03 and <0.01, respectively, versus 0.51 and 0.35 for the 400 mg regimen, respectively. The probability of achieving PK-PD target exposures against S. pneumoniae in patients aged 65 years receiving the 200 mg regimen was 0.99.
Conclusions: The probability of a patient aged 65 years having an AUC0–24 60–70 mg•h/L is markedly lower following a 200 mg regimen relative to a 400 mg regimen, suggesting a decreased risk of severe hyperglycaemia in a predisposed patient. Moreover, a dose reduction does not appear to significantly modify the likelihood of achieving the PK-PD target of gatifloxacin against S. pneumoniae.
Keywords: hyperglycaemia, pharmacokinetic model, fluoroquinolones
* Corresponding author. Tel: +1-716-633-3463, ext. 302; Fax: +1-716-633-7404; E-mail: paul.ambrose{at}cognigencorp.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J Mehlhorn and D. A Brown Safety Concerns with Fluoroquinolones Ann. Pharmacother., November 1, 2007; 41(11): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Edwards, R. G. Hall, and M. E. Ceja Gatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature Journal of Pharmacy Practice, February 1, 2007; 20(1): 93 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Zvonar Gatifloxacin-induced dysglycemia. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2087 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, B. R. Overholser, M. B. Kays, and K. M. Sowinski Gatifloxacin pharmacokinetics in healthy men and women. J. Clin. Pharmacol., October 1, 2006; 46(10): 1154 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y. Park-Wyllie, D. N. Juurlink, A. Kopp, B. R. Shah, T. A. Stukel, C. Stumpo, L. Dresser, D. E. Low, and M. M. Mamdani Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults N. Engl. J. Med., March 30, 2006; 354(13): 1352 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L Blommel and R. A Lutes Severe Hyperglycemia During Renally Adjusted Gatifloxacin Therapy Ann. Pharmacother., July 1, 2005; 39(7): 1349 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Happe, B. P. Mulhall, C. L. Maydonovitch, and K. C. Holtzmuller Gatifloxacin-Induced Hyperglycemia Ann Intern Med, December 21, 2004; 141(12): 968 - 699. [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Smith, A. M. Noreddin, C. G. Siemens, K. N. Schurek, J. Greisman, C. J. Hoban, D. J. Hoban, and G. G. Zhanel Designing Fluoroquinolone Breakpoints for Streptococcus pneumoniae by Using Genetics instead of Pharmacokinetics-Pharmacodynamics Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3630 - 3635. [Abstract] [Full Text] [PDF]
|
|